Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease
Overview
Neurology
Authors
Affiliations
Background: Neurofibrillary tangles (NFTs) and amyloid plaques are the neuropathological hallmarks in brains with Alzheimer's disease (AD). Post-translational modifications of tau, such as phosphorylation and truncation, have been proposed as initiators in the assembly of the abnormal paired helical filaments that constitute the NFTs. Neurons and NFTs are sites of matrix metalloproteinases (MMPs).
Objective: The aim of this study was to analyze the relationship of MMP-9 and tau protein in brain samples with AD.
Methods: This study was performed on brain tissue samples from patients with early, moderate, and late AD. MMPs and tau levels were analyzed by western blot and gelatin-substrate zymography. Immunofluorescence techniques and confocal microscopy were used to analyze the presence of both proteins in NFTs. Further, molecular dynamics simulations (MDS) and protein-protein docking were conducted to predict interaction between MMP-9 and tau protein.
Results: MMP-9 expression was greatest in moderate and late AD, whereas MMP-2 expression was only increased in late-stage AD. Interestingly, confocal microscopy revealed NFTs in which there was co-localization of MMP-9 and tau protein. MDS and protein-protein docking predictions indicate that a high-affinity complex can be formed between MMP-9 and full-length tau protein.
Conclusion: These observations provide preliminary evidence of an interaction between these two proteins. Post-translational modifications of tau protein, such as C-terminal truncation or phosphorylation of amino acid residues in the MMP-9 recognition site and conformational changes in the protein, such as folding of the N-terminal sequence over the three-repeat domain, could preclude the interaction between MMP-9 and tau protein during stages of NFT development.
Investigation of the role of miRNA variants in neurodegenerative brain diseases.
Frydas A, Cacace R, van der Zee J, Van Broeckhoven C, Wauters E Front Genet. 2025; 16:1506169.
PMID: 40078479 PMC: 11897046. DOI: 10.3389/fgene.2025.1506169.
Fontan-Baselga T, Caneque-Rufo H, Rivera-Illades E, Gramage E, Zapico J, de Pascual-Teresa B Front Pharmacol. 2024; 15:1506049.
PMID: 39712494 PMC: 11658987. DOI: 10.3389/fphar.2024.1506049.
Gall Z, Boros B, Kelemen K, Urkon M, Zolcseak I, Marton K Front Pharmacol. 2024; 15:1447757.
PMID: 39135795 PMC: 11317391. DOI: 10.3389/fphar.2024.1447757.
The Inflammation-Induced Dysregulation of Reelin Homeostasis Hypothesis of Alzheimer's Disease.
Reive B, Lau V, Sanchez-Lafuente C, Henri-Bhargava A, Kalynchuk L, Tremblay M J Alzheimers Dis. 2024; 100(4):1099-1119.
PMID: 38995785 PMC: 11380287. DOI: 10.3233/JAD-240088.
The Link Between Matrix Metalloproteinases and Alzheimer's Disease Pathophysiology.
Radosinska D, Radosinska J Mol Neurobiol. 2024; 62(1):885-899.
PMID: 38935232 PMC: 11711632. DOI: 10.1007/s12035-024-04315-0.